BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 15161699)

  • 1. Genetic and epigenetic changes in p21 and p21B do not correlate with resistance to doxorubicin or mitomycin and 5-fluorouracil in locally advanced breast cancer.
    Staalesen V; Leirvaag B; Lillehaug JR; Lønning PE
    Clin Cancer Res; 2004 May; 10(10):3438-43. PubMed ID: 15161699
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The novel p21 polymorphism p21G251A is associated with locally advanced breast cancer.
    Staalesen V; Knappskog S; Chrisanthar R; Nordgard SH; Løkkevik E; Anker G; Ostenstad B; Lundgren S; Risberg T; Mjaaland I; Gram IT; Kristensen VN; Børresen-Dale AL; Lillehaug JR; Lønning PE
    Clin Cancer Res; 2006 Oct; 12(20 Pt 1):6000-4. PubMed ID: 17062672
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influence of TP53 gene alterations and c-erbB-2 expression on the response to treatment with doxorubicin in locally advanced breast cancer.
    Geisler S; Lønning PE; Aas T; Johnsen H; Fluge O; Haugen DF; Lillehaug JR; Akslen LA; Børresen-Dale AL
    Cancer Res; 2001 Mar; 61(6):2505-12. PubMed ID: 11289122
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TP53 gene mutations predict the response to neoadjuvant treatment with 5-fluorouracil and mitomycin in locally advanced breast cancer.
    Geisler S; Børresen-Dale AL; Johnsen H; Aas T; Geisler J; Akslen LA; Anker G; Lønning PE
    Clin Cancer Res; 2003 Nov; 9(15):5582-8. PubMed ID: 14654539
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mutations and polymorphisms of the p21B transcript in breast cancer.
    Knappskog S; Chrisanthar R; Staalesen V; Børresen-Dale AL; Gram IT; Lillehaug JR; Lønning PE
    Int J Cancer; 2007 Aug; 121(4):908-10. PubMed ID: 17443496
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Overexpression of p27 protein in human breast cancer correlates with in vitro resistance to doxorubicin and mitomycin C.
    Yang Q; Sakurai T; Yoshimura G; Takashi Y; Suzuma T; Tamaki T; Umemura T; Nakamura Y; Nakamura M; Utsunomiya H; Mori I; Kakudo K
    Anticancer Res; 2000; 20(6B):4319-22. PubMed ID: 11205265
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeted cytotoxic somatostatin analogue AN-238 inhibits somatostatin receptor-positive experimental colon cancers independently of their p53 status.
    Szepeshazi K; Schally AV; Halmos G; Armatis P; Hebert F; Sun B; Feil A; Kiaris H; Nagy A
    Cancer Res; 2002 Feb; 62(3):781-8. PubMed ID: 11830533
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor progression through epigenetic gene silencing of O(6)-methylguanine-DNA methyltransferase in human biliary tract cancers.
    Koga Y; Kitajima Y; Miyoshi A; Sato K; Kitahara K; Soejima H; Miyazaki K
    Ann Surg Oncol; 2005 May; 12(5):354-63. PubMed ID: 15915369
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor suppressor gene promoter hypermethylation in serum of breast cancer patients.
    Dulaimi E; Hillinck J; Ibanez de Caceres I; Al-Saleem T; Cairns P
    Clin Cancer Res; 2004 Sep; 10(18 Pt 1):6189-93. PubMed ID: 15448006
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evasion of a single-step, chemotherapy-induced senescence in breast cancer cells: implications for treatment response.
    Elmore LW; Di X; Dumur C; Holt SE; Gewirtz DA
    Clin Cancer Res; 2005 Apr; 11(7):2637-43. PubMed ID: 15814644
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The transglutaminase 2 gene (TGM2), a potential molecular marker for chemotherapeutic drug sensitivity, is epigenetically silenced in breast cancer.
    Ai L; Kim WJ; Demircan B; Dyer LM; Bray KJ; Skehan RR; Massoll NA; Brown KD
    Carcinogenesis; 2008 Mar; 29(3):510-8. PubMed ID: 18174247
    [TBL] [Abstract][Full Text] [Related]  

  • 12. RNA interference-mediated silencing of the p53 tumor-suppressor protein drastically increases apoptosis after inhibition of endogenous fatty acid metabolism in breast cancer cells.
    Menendez JA; Lupu R
    Int J Mol Med; 2005 Jan; 15(1):33-40. PubMed ID: 15583825
    [TBL] [Abstract][Full Text] [Related]  

  • 13. DNA methylation status of key cell-cycle regulators such as CDKNA2/p16 and CCNA1 correlates with treatment response to doxorubicin and 5-fluorouracil in locally advanced breast tumors.
    Klajic J; Busato F; Edvardsen H; Touleimat N; Fleischer T; Bukholm I; Børresen-Dale AL; Lønning PE; Tost J; Kristensen VN
    Clin Cancer Res; 2014 Dec; 20(24):6357-66. PubMed ID: 25294903
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of RUNX3 gene, methylation status and clinicopathological significance in breast cancer and breast cancer cell lines.
    Jiang Y; Tong D; Lou G; Zhang Y; Geng J
    Pathobiology; 2008; 75(4):244-51. PubMed ID: 18580070
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Methylation-associated silencing of death-associated protein kinase gene in laryngeal squamous cell cancer.
    Kong WJ; Zhang S; Guo C; Zhang S; Wang Y; Zhang D
    Laryngoscope; 2005 Aug; 115(8):1395-401. PubMed ID: 16094112
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A single recombinant adenovirus expressing p53 and p21-targeting artificial microRNAs efficiently induces apoptosis in human cancer cells.
    Idogawa M; Sasaki Y; Suzuki H; Mita H; Imai K; Shinomura Y; Tokino T
    Clin Cancer Res; 2009 Jun; 15(11):3725-32. PubMed ID: 19458054
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Altered expression of proliferation-inducing and proliferation-inhibiting genes might contribute to acquired doxorubicin resistance in breast cancer cells.
    Saleh EM; El-Awady RA; Abdel Alim MA; Abdel Wahab AH
    Cell Biochem Biophys; 2009; 55(2):95-105. PubMed ID: 19593673
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cell-type-specific responses to chemotherapeutics in breast cancer.
    Troester MA; Hoadley KA; Sørlie T; Herbert BS; Børresen-Dale AL; Lønning PE; Shay JW; Kaufmann WK; Perou CM
    Cancer Res; 2004 Jun; 64(12):4218-26. PubMed ID: 15205334
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epigenetic inactivation of ID4 in colorectal carcinomas correlates with poor differentiation and unfavorable prognosis.
    Umetani N; Takeuchi H; Fujimoto A; Shinozaki M; Bilchik AJ; Hoon DS
    Clin Cancer Res; 2004 Nov; 10(22):7475-83. PubMed ID: 15569977
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Down-regulation of LATS1 and LATS2 mRNA expression by promoter hypermethylation and its association with biologically aggressive phenotype in human breast cancers.
    Takahashi Y; Miyoshi Y; Takahata C; Irahara N; Taguchi T; Tamaki Y; Noguchi S
    Clin Cancer Res; 2005 Feb; 11(4):1380-5. PubMed ID: 15746036
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.